Advertisement
Advertisement
U.S. Markets open in 9 mins
Advertisement
Advertisement
Advertisement
Advertisement

Sunshine Biopharma, Inc. (SBFM)

Other OTC - Other OTC Delayed Price. Currency in USD
Add to watchlist
0.0535-0.0055 (-9.32%)
At close: 03:59PM EST
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close0.0590
Open0.0590
Bid0.0000 x 0
Ask0.0000 x 0
Day's Range0.0510 - 0.0600
52 Week Range0.0128 - 0.3140
Volume1,996,987
Avg. Volume2,469,487
Market Cap25.707M
Beta (5Y Monthly)-3.11
PE Ratio (TTM)N/A
EPS (TTM)-0.0290
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    Sunshine Biopharma Expands Board of Directors

    Independent Directors Added as Part of Company’s Application Process to Uplist to NasdaqMONTREAL, Nov. 03, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has expanded its board of directors from three to five and has appointed three new, independent directors. The three new directors are: Mr. Andrew Tesley, Esq, Mr. JD Kish, CPA and Dr

  • GlobeNewswire

    Sunshine Biopharma Files a Patent Application Covering mRNA Molecules for Treatment of Neurodegenerative Diseases

    MONTREAL, Oct. 06, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC PINK: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs, today announced that it has filed a patent application for a potential new treatment for neurodegenerative disorders. Sunshine Biopharma’s patent application contains experimental results showing that certain mRNA molecules provide protective effects against oxidative stress in differentiated n

  • GlobeNewswire

    Sunshine Biopharma’s Coronavirus Treatment Anticipated to be Effective Against Delta and the Other Variants of Concern

    MONTREAL, Aug. 12, 2021 (GLOBE NEWSWIRE) -- Sunshine Biopharma Inc. (OTC Pink: “SBFM”), a pharmaceutical company focused on the research, development and commercialization of oncology and antiviral drugs today announced that it mapped the mutations found in Delta and the other variants of concern (“VOC”) identified to date and determined that the majority of the mutations are in the Spike protein and only a few fall within the genomic sequences that encode nsp3, a multi-domain protein that inclu

Advertisement
Advertisement